January 27, 2025 10:25 AM EST
News Briefing

Al­lakos re­struc­tures af­ter Phase 1 fail­ure; AB2 inks deal with Nip­pon Shinyaku

Max Gelman

Senior Editor

Anna Brown

News Reporter

Plus, news about GSK:

Al­lakos re­ports Phase 1 fail­ure, lays off 75% of staff: The biotech said AK006 did not pro­duce …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

One Feb­ru­ary FDA ad­comm meet­ing is de­layed, an­oth­er can­celed

The RFK ques­tion: Trump's HHS nom­i­nee splits bio­phar­ma be­fore mo­ment of truth

Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter 

No­vo Nordisk asks Third Cir­cuit to ex­pe­dite IRA case as par­tic­i­pa­tion dead­line looms

Ozem­pic la­bel ex­pand­ed to in­clude re­duced risk of wors­en­ing kid­ney dis­ease

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times